16217-22-4Relevant articles and documents
Design, synthesis, and biological evaluation of novel phenol ether derivatives as non-covalent proteasome inhibitors
Yu, Jianjun,Xu, Lei,Hong, Duidui,Zhang, Xiaotuan,Liu, Jieyu,Li, Daqiang,Li, Jia,Zhou, Yubo,Liu, Tao
, p. 543 - 558 (2019)
A series of novel phenol ether derivatives were designed, synthesized, and evaluated as non-covalent proteasome inhibitors. Most compounds exhibited moderate to excellent proteasome inhibitory activity. In particular, compound 18x proved to be the most po
1,4-Palladium Shift/C(sp3)-H Activation Strategy for the Remote Construction of Five-Membered Rings
Rocaboy, Ronan,Baudoin, Olivier
supporting information, p. 1434 - 1437 (2019/02/19)
1,n-Metal shift is an elegant alternative approach enabling the functionalization of remote C-H bonds from simple precursors. In this work, we report a novel and simple Pd0-catalyzed domino reaction involving 1,4-palladium shift and C(sp3)-H activation and leading to (fused) five-membered rings. This method allowed access to a broad range of valuable arylidene γ-lactams and indanones and was applied to the formal synthesis of (-)-pyrrolam.
COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY
-
Paragraph 590; 591-592, (2017/01/31)
The present invention provides novel compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases, e.g., cancers (e.g., breast cancer, prostate cancer, lymphoma, lung cancer, pancreatic cancer, ovarian cancer, neuroblastoma, or colorectal cancer), benign neoplasms, angio genesis, inflammatory diseases, fibrosis (e.g., polycystic kidney disease), autoinflammatory diseases, and autoimmune diseases in a subject.
